VACCINEX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.79 USD | +30.58% |
|
+25.74% | -27.05% |
| 05-16 | Earnings Flash (VCNX) VACCINEX Reports Q1 Revenue $104,000 | MT |
| 04-12 | Vaccinex, Inc. announced that it has received $1.75 million in funding | CI |
Vaccinex, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. Its lead product candidate, pepinemab, is in clinical development for the treatment of Alzheimerâs disease, head and neck, pancreatic and breast cancer. Its lead platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop pepinemab for the treatment of various diseases and conditions, including cancer. ActivMAb antibody discovery platform is a human antibody discovery platform based on a method for expressing multipass membrane proteins, as well as large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of mammalian pox viruses.
Calendar
11/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -27.05% | 8.24M | |
| +11.91% | 114B | |
| +11.60% | 105B | |
| -4.68% | 23.83B | |
| -0.82% | 21.73B | |
| -10.12% | 18.1B | |
| -42.12% | 16.34B | |
| -17.47% | 16.13B | |
| +2.77% | 13.75B | |
| +34.58% | 11.76B |
- Stock Market
- Equities
- VCNX Stock
- News Vaccinex, Inc.
- Earnings Flash (VCNX) VACCINEX Reports Q1 Revenue $104,000
